Fact CheckerSign in

NCT06853145RecruitingEarly phase 1

Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis

Source: ClinicalTrials.gov · Last updated 9 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.

Status (registry)
Recruiting
Phase (registry)
Early phase 1
Study type
Interventional
Enrollment
6 (estimated)
First submitted
1 Nov 2024
Start date
1 May 2025
Primary completion date
Dec 2026
Lead sponsor
University of Virginia
NCT number
NCT06853145

What you commit to

  • Study type: Interventional · Early phase 1
  • Planned participants: 6
  • From 1 May 2025 to the primary completion date, Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.
  • History of respiratory infection within 2 weeks prior to the MR scan

Other illness

  • History of congenital cardiac disease, chronic renal failure, or cirrhosis. • Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches.
  • History of MI, stroke and/or poorly controlled hypertension.

Other

  • Continuous oxygen use at home
  • Oxygen saturation less than 92% on the day of MRI procedure
  • Pregnancy or lactation
  • Inability to understand simple instructions or to hold still for approximately 10-15 seconds.

Who the study is looking for

  • Able to provide informed consent 18 years of age or greater Clinical diagnosis of IPF

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Snyder Building 480 Ray C. Hunt Drive
Coordinator of this site? Confirm its status
CharlottesvilleUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.